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ABSTRACT  
Non-steroidal anti-inflammatory drugs (NSAIDs) can damage the gastrointestinal 
tract, causing widespread morbidity and mortality. Although mechanisms of damage 
involve the activities of prostaglandin-endoperoxide synthase 1 (PTGS1 or COX1) 
and PTGS1 (COX2), other factors are involved. We review mechanisms of gastroin-
testinal damage induction by NSAIDs, via COX-mediated and COX-independent 
processes. NSAIDs interact with phospholipids and uncouple mitochondrial oxidative 
phosphorylation, which initiates biochemical changes that impair function of the gas-
trointestinal barrier. The resulting increase in intestinal permeability leads to low-
grade inflammation. NSAID’s inhibition of COX enzymes, along with luminal aggres-
sors, results in erosions and ulcers, with potential complications of bleeding, protein 
loss, stricture formation, and perforation. We propose a model for NSAID-induced 
damage to the gastrointestinal tract that includes these complex, interacting, and in-
ter-dependent factors. This model highlights the obstacles for the development of 
safer NSAIDs. 
 
Key words: GI; prostaglandin; drug-induced intestinal damage; bacteria, bile acids
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More than 30 million people take non-steroidal anti-inflammatory drugs (NSAIDs) 
each day (1). This number has grown significantly with increasing use of over the 
counter and prescription NSAIDs, low-dose aspirin and following reports of their po-
tential anti-neoplastic effects. The efficacy of NSAIDs as anti-inflammatory analge-
sics is not in doubt, but their adverse events are problematic. These relate mainly to 
cardiovascular, renal, hepatic, and the gastrointestinal tissues. The cardiovascular 
adverse events have recently received much attention (2, 3), but the frequency and 
severity of the gastrointestinal damage continues to cause concern.  Accordingly the 
range of gastroduodenal ulcer rates range from 5% to 80% in short-term endoscopy 
studies (4) and from 15% to 40% in long-term users (5). NSAIDs also damage the 
small intestine (6)—as many as 70% of long-term users of NSAIDs have small intes-
tinal inflammation, and 30% have erosions or ulcers (7). The gastric and small bowel 
damage is associated with various management problems and at times life threaten-
ing complications, such as bleeding, strictures and perforations. 
There have been many studies of the pathogenesis of NSAID-induced gastro-
intestinal damage. NSAIDs inhibit prostaglandin-endoperoxide synthase 1 (PTGS1 
or COX1) and COX2, which have been believed to mediate the gastrointestinal 
damage (8-10). NSAID-induced decreases in mucosal levels of prostaglandins (driv-
en by inhibition of COX1) correlate with gastric and small bowel damage (11-13), 
which can be attenuated by administration of exogenous prostaglandins (14-18). 
Since COX2 is not constitutively expressed in the gastrointestinal tract COX2 selec-
tive inhibitors are perceived as safer than conventional NSAIDs (14, 15, 19, 20). 
Proposed mechanisms of damage to the stomach involve prostaglandin mediated 
increased gastric acid secretion, decreased mucus and bicarbonate secretion, de-
creased cell proliferation, and decreased mucosal blood flow (21-24). These are all 
actions that are detrimental to mucosal defense and healing, but the observed 
changes were only modest (21, 23, 25-30) and the damage seemed to lack an initia-
tive action. Furthermore, decreased mucosal prostaglandins have been fund to be 
less important in the pathogenesis of the small bowel damage (11, 31, 32). 
Further studies showed that gastric and small bowel mucosal prostaglandins 
could be decreased by 95%–98% without mucosal damage (33-35), confirmed in 
COX1-knockout mice (35-37). Short-term loss or inhibition of COX2 does not cause 
damage, but small bowel damage is evident in mice and humans exposed to 
NSAIDs for long periods of time (38-41). Dual inhibition of COX1 and COX2 causes 
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gastric and small bowel lesions, albeit somewhat less severe than that the lesions 
caused by conventional acidic NSAIDs (36).  
So, inhibition of COX does not seem to be the only mechanism of NSAID-induced 
gastrointestinal damage. We review the prostaglandin-independent mechanisms of 
NSAIDs and how these interact with the consequence of alterations in prostaglandin 
levels as a consequence of COX inhibition. We provide a model in which COX inhibi-
tion is one of several important factors in the pathogenesis of gastrointestinal dam-
age (see Figure 1). Our model considers the effects of the specific biochemical “topi-
cal” effects of NSAIDs (i.e. the effects that occur by direct contact between the 
NSAIDs in the lumen and mucosal epithelium following oral ingestion and/or biliary 
excretion of the drugs, as opposed to topical skin application) and the consequential 
increase in intestinal permeability and intestinal inflammation. These initiate damage 
and inhibition of COX1 and COX2 aggravate it, along with luminal aggressors, lead-
ing to development of erosions and ulcers (42, 43).  
BIOCHEMICAL EFFECTS OF NSAIDS 
The biochemical actions common to all conventional NSAIDs are their “topical” ef-
fects, and inhibition of COX1 and COX2. These biochemical actions are brought 
about by the physicochemical properties that NSAIDs share (44-46), namely being 
lipid soluble weak acids (see Figure 2). This combination provides them with deter-
gent action (interaction with phospholipids), uncoupling of oxidative phosphorylation, 
and non-covalent inhibition of COX1 and COX2. These biochemical activities depend 
on the same physical and chemical characteristics, so changing these will change all 
the pharmacologic actions. For example, esterification of NSAIDs (47) causes loss of 
their “topical” effects and at the same time their ability to inhibit the COX enzymes.  
Interactions between NSAIDs and phospholipids 
NSAIDs interact with the intestinal mucus layer and the cell surface phospholipid bi-
layer. There are subtle differences in mucus thickness and composition in different 
regions of the gastrointestinal tract (19, 48). The role of mucus is to act as a lubricant 
between the surface epithelium and the luminal contents, restricting access of large 
hydrophilic molecules, digestive enzymes, and bacteria to the surface epithelium. In 
the stomach, mucus also buffers luminal acids. The production and secretion of mu-
cus is determined by interactions between luminal aggressors (acid, pepsin, H pylori 
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in the stomach and bile and bacteria in the small bowel) and the surface epithelium 
mediated by numerous factors such as inflammatory cytokines and prostaglandins.  
Mucus serves as a matrix for phospholipids that maintain gastrointestinal in-
tegrity (49). Like NSAIDs, phospholipids are amphiphilic molecules, with a hydro-
philic polar head group and a hydrophobic tail region. The integrity of the mucus lay-
er can be assessed by various methods (50). NSAIDs decreased the hydrophobicity 
in the gastroduodenal mucosa (51), an effect seen also after parenteral administra-
tion via the biliary excretion of the drug (52). The interaction between NSAIDs and 
phospholipids compromises the hydrophobic lining, which leads to mucosal expo-
sure to luminal aggressors (acid and pepsin in the stomach and bacteria and bile in 
the small intestine).  
The concept of a hydrophobic barrier attributed to phospholipids and the bind-
ing of NSAIDs to dipalmitoylphosphatidylcholine (the dominant phospholipid in the 
gastrointestinal-tract), in vitro and in vivo (49, 53), led to a series of studies investi-
gating the effect of orally co-administrated phospholipids with NSAIDs, and other tox-
ic compounds, with a view to diminishing their toxicity. Combining NSAIDs with the 
phospholipid phosphatidylcholine protects against NSAID-induced gastric (49, 54) 
and small bowel (55) damage in short-term rodent studies. Lichtenberger et al 
demonstrated decreased gastric toxicity of the otherwise damaging combination of 
aspirin and a COX2-selective agent, if the aspirin was co-administered with a phos-
pholipid (56).  
These and other animal studies provided the platform for testing the safety of 
NSAIDs combined with phospholipids in humans. Volunteers were given aspirin or a 
combination of aspirin and phospholipid (650 mg aspirin/day for 3 days). The number 
of gastric erosions (assessed during endoscopy) was significantly lower in volunteers 
given aspirin and phospholipid (mean 2.8 ± 4.3) than aspirin alone (mean 8.8 ± 10.8; 
both drugs reduced mucosal prostaglandin content to the same extent (57). In a 
separate study, healthy volunteers given aspirin (325 mg/day for 7 days) or the same 
amount of aspirin combined with phosphatidylcholine, had a significant decrease in 
gastric ulcers, from 17.6% in volunteers given aspirin to 5.1% in volunteers given as-
pirin with phosphatidylcholine (58). In a 6-week study of patients with osteoarthritis, 
the combination of ibuprofen and phosphatidylcholine was associated with significant 
improvements in Lanza gastroscopy scores, compared to patients given ibuprofen 
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(2400 mg) alone, but only in patients older than 55 years (59). These studies 
demonstrated greater gastric tolerability of combinations of aspirin and phospholipid, 
in the short-term, in humans, in which damage is more likely to be caused by the 
physicochemical properties of NSAIDs than their effect on COX1 or COX2 (4).  
Uncoupling mitochondrial oxidative phosphorylation 
Mitochondria are the main source of ATP in cells. Mitochondrial ATP synthesis takes 
place by integrated biochemical-physiological-physical processes (60) (see Figure 
3). 
Whatever the cause of uncoupling there is a cascade of detrimental down-
stream effects: water flows into the matrix, causing characteristic and pathognomon-
ic swelling of mitochondria. There is release of intra-mitochondrial Ca2+ into cyto-
plasm with depletion of reduced glutathione, depletion of NAD(P)H2, generation of 
superoxide anion (O2–) and release of pro-apoptogenic proteins (61). Free radicals 
accumulate within the mitochondria setting up a vicious cycle as this activates un-
coupling proteins in the inner mitochondrial membrane (62). The uncoupling ulti-
mately leads to depletion of cellular ATP levels, with loss of integrity of the intercellu-
lar junctions in the gastrointestinal tract (leading to increased mucosal permeability) 
(63), and ultimately apoptosis and cell death (64).  
Well before the understanding that NSAIDs inhibited the COX enzyme(s) it 
was evident that NSAIDs were uncouplers of mitochondrial oxidative phosphorylation 
(65, 66). Adams et al screened possible anti-inflammatory agents based on their un-
coupling properties and several (such as ibuprofen, naproxen and indomethacin) 
have been marketed on that basis. However, the idea of the uncoupling action of 
NSAIDs as a mechanism for their therapeutic actions became obsolete when the 
prostaglandin hypothesis gained momentum.  
A few reports describe uncoupling of mitochondrial oxidative phosphorylation 
in the gastric mucosa following aspirin (67, 68). Using the technique of selective sub-
cellular marker enzyme analyses of small bowel mucosa following administration of 
NSAIDs in animals (69) showed a significant change in the brush border marker en-
zyme, compatible with the interaction of NSAIDs with phospholipids, and the mito-
chondrial marker enzymes.  Electron microscopic changes of uncoupling were 
demonstrated in vivo after administration of NSAIDs to rats (69). The in vitro uncou-
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pling of conventional acidic (carboxylic or enolic acids) NSAIDs relates to their pKa 
values (see Table 1) (70). Drugs that are purported to be safer such as paracetamol 
(non acidic analgesic), nabumetone (a non-acidic NSAID pro-drug (71), and esteri-
fied non-acidic pro-NSAIDs (see Figure 2), such as nitro-butyril flubiprofen are not 
uncouplers in vitro (69).  
Micromolar to millimolar concentrations of NSAIDs have the ability to uncou-
ple mitochondrial oxidative phosphorylation in vitro (42, 69, 72-76), due to ion trap-
ping during absorption (see Figure 4). COX2-selective agents also uncouple oxida-
tive phosphorylation in vitro and in cell systems, but with lower potency than that of 
acidic NSAIDs (76, 77). The uncoupling by NSAIDs was demonstrated by electron 
microscopy in the small bowel of mice given conventional acidic NSAIDs (42, 69, 73-
75, 78, 79) and similar changes are also found in gastric biopsies from patients (67, 
68, 80-83). No studies have assessed the possible prevention of uncoupling brought 
about by NSAIDs. 
INHIBITION OF COX1 AND 2 AND ROLE OF PROSTAGLANDINS 
The 3-dimensional structure of the COX enzymes reveals the active site of both COX 
isoforms to be at the end of a hydrophobic channel. NSAIDs inhibit the enzyme by 
blocking the entrance of arachidonic acid to this channel and thereby denying sub-
strate access to the active site (84, 85). The COX1 and 2 channels differ. Conven-
tional NSAIDs have access to both channels and form an ionic bond via their car-
boxyl or enolic group (86). The COX1 channel is smaller than the channel in COX2 
and does not accommodate COX2-selective agents, but a side pocket in the COX2 
enzyme has a polar binding site (87) for the aryl sulfonamide and sulfone moieties of 
the COX2-selective agents.  
The most damaging consequence of decreased prostaglandin production with 
COX inhibition could be the effects on the microcirculation. Regulation and mainte-
nance of the intestinal microcirculation is complex involving several interacting bio-
chemical mechanisms. The most relevant mediators are prostaglandins, leukotri-
enes, nitric oxide, and hydrogen sulphide. NSAID-induced prevention of physiologi-
cal compensatory increases in blood flow (leading to tissue hypoxia) following injury 
is well described. The effects of nitric oxide and hydrogen sulphide are remarkably 
similar to that of prostaglandins, namely increased microvascular blood flow, in-
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creased mucus secretion, and a modest decrease of gastric acid secretion (88, 89). 
Targeting these processes with nitric oxide donors such as nitro-glycerine, nitroprus-
side, nitric-oxide-NSAIDs, and hydrogen sulphite NSAIDs can reduce the gastroin-
testinal damage due to NSAIDs in laboratory animals (27, 90-93). Presumably these 
effects counteract the reduced microvascular blood flow (94) consequent to NSAID-
induced decreased prostaglandins (95). Proof-of-concept endoscopic studies of 
healthy volunteers showed that nitric oxide donors and NSAIDs reduced gastroduo-
denal damage, compared with NSAIDs (96, 97), but the results of a longer-term clin-
ical trial did not show statistically significant differences (98). 
Another vascular effect of NSAIDs involves NSAID-induced expression of 
neutrophil adhesion molecules within the endothelium (common to most intestinal 
inflammatory conditions) (27, 29, 93, 99). Neutrophil accumulation could mechanical-
ly compromise microvascular blood flow. Nitric oxide and hydrogen sulphite are, like 
prostaglandins, inhibitors of leucocyte adhesion to the vascular endothelium (100).  
However, vascular effects are probably not the primary or initiating event in 
NSAID-induced gastrointestinal damage. The effects on the vasculature cannot ac-
count for the selective localization of the macroscopic damage (101-104) within the 
gastrointestinal tract nor the mesenteric rather than the anti-mesenteric location of 
small bowel ulcers. The damage also differs macroscopically and microscopically 
from ischemic damage. The suggestion that neutrophil adhesion to the vessel wall (a 
COX2-mediated effect) is a primary event in the damage is difficult to reconcile with 
the fact that COX2 is not constitutively expressed in the gastrointestinal tract. Fur-
thermore, neutrophil adhesion to the intestinal vessel wall does not automatically in-
dicate damage as neutrophils require a chemoattractant for activation-degranulation 
and hence damage (105, 106). 
Consequences of the biochemical effects of NSAIDs 
Studies on COX-knockout mice have increased our understanding of the conse-
quences of COX1 and COX2 deficiency. Absence or selective inhibition of COX1 (by 
the non-acidic COX1 inhibitor, SC-560) reduced levels of prostaglandins by 95% or 
more, which was not associated with increased intestinal permeability, inflammation, 
or ulcers (35, 36). Neither was short-term, selective deletion or inhibition of COX2 
(36, 39). These findings should be considered alongside studies that assess the 
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consequences of the “topical” effects and dissociated these from the consequences 
of COX inhibition. These studies were done by comparing key pathophysiological 
events in the damage, namely the “topical” effect (in vitro and in vivo uncoupling), 
prostaglandin levels, intestinal permeability, and inflammation following the use of 
selective drugs. This provides convincing evidence that the “topical” effects (phos-
pholipid-NSAID interaction and uncoupling) initiate gastrointestinal damage, but only 
with COX1 inhibition (in association with luminal aggressive factors), does this lead 
to mucosal erosions and ulcers. The compounds and their effects can be catego-
rized as follows (see Table 2): 
• Selective uncouplers (dinitrophenol [DNP] or R-flurbiprofen) can increase 
intestinal permeability associated with mild inflammation, but do not signifi-
cantly alter mucosal prostaglandin levels, and do not cause mucosal ulcer-
ation. 
• Uncouplers (conventional acidic NSAIDs) that inhibit COX enzymes are as-
sociated with increased intestinal permeability, inflammation, and ulcers.  
• COX2-selective agents such as celecoxib do not uncouple oxidative phos-
phorylation (nimesulide with a Pka of 6.4, despite showing uncoupling activ-
ity, behaves like celecoxib—possibly because the uncoupling effect in vivo 
affects only a few mitochondria). These agents are not associated with in-
creased intestinal permeability, inflammation or ulcers. 
Collectively these studies, together with studies of knockout mice, have provided 
compelling evidence that uncoupling of mitochondrial oxidative phosphorylation 
(along with the NAID-phospholipid interaction) increases intestinal permeability and 
low-grade inflammation. Decreased mucosal prostaglandin production and the mu-
cosal aggressors lead to more severe inflammatory and ulcerative damage, perhaps 
via effects on the microcirculation.  
The findings from COX2-knockout mice are more difficult to explain. These 
mice have normal mucosal levels of prostaglandin, but half have normal intestinal 
permeability and no inflammation or intestinal ulcers, and the other half develop 
small intestinal inflammation and ulcers or die because of ulcer perforation. Similar 
findings were seen with long-term administration of a selective COX2 inhibitor to 
wild-type mice. COX2 inhibition also leads to enteropathy in humans (41). 
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TISSUE REACTION AND ROLE OF LUMINAL AGGRESSORS 
The tissue reaction is characterized by inflammation and the presence of erosions 
and ulcers and this appears to be driven by COX inhibition and the luminal aggres-
sive factors. The luminal aggressors differ between the stomach (acid, pepsin, and H 
pylori) and small bowel (bile and commensal bacteria). The importance of gastric lu-
minal aggressors is widely appreciated, but the same does not hold true for small 
bowel aggressors. Our review focuses on effects in the small bowel. 
Role of acid and H pylori in NSAID-induced gastropathy 
The importance of gastric acid in the damage of NSAID-induced gastro-duodenal 
damage in humans is amply demonstrated clinically in the reduced incidence of 
damage (short and long-term) and serious ulcer outcomes when NSAIDs are co-
administered with proton pump inhibitors (107, 108) or high dose histamine receptor-
2 inhibitors (109). In the context of the current pathogenic model the macroscopic 
damage in the stomach is principally due to back diffusion of acid due to the im-
paired barrier function (brought about by the “topical” effects) induced by NSAIDs 
and amplified by the prostaglandin dependent effects induced by NSAIDs. The fre-
quent finding of chemical gastritis (reactive gastritis) in antral biopsies in patients on 
NSAIDs (110), who do not have H pylori infection, can be considered as the conse-
quence of the “topical” effect of these drugs. In this context, the mucosal inflammato-
ry reaction is weak compared to that seen in patients infected by H pylori. 
 The effects of H pylori infection in the pathogenesis of NSAID-associated gas-
tric ulcers is controversial. H pylori does not seem to mediate development of short-
term NSAID-induced gastric damage in humans (4), although it may affect gastric 
adaptation to short-term administration of aspirin (111). Gastric damage induced by 
long-term NSAIDs or aspirin occurs in addition to the gastritis induced by H pylori in-
fection, which occurs early in life. H pylori induces gastric mucosal lesions by inter-
acting with the immune response (112). The intrinsic virulence factors of each specif-
ic H pylori strain may induce a weak or a strong host immune cytokine-mediated in-
flammatory response, which is genetically determined. Patients infected by H pylori  
may develop pangastritis or antral predominant gastritis, which affect acid secretion 
levels. Pangasritis is usually associated with normal or reduced gastric acid secre-
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tion whereas antral predominant gastritis is associatd with increased acid secretion 
due to a decrease in somatostantin and increased gastrin secretion (113, 114). 
Therefore, the type of gastritis associated with H pylori may explain the contradictory 
results obtained in different clinical studies (113, 114). H pylori exacerbates aspirin-
induced gastric damage associated with normal or increased gastric acid secretion 
but reduces the damage in patients who became hyposecretors (115). A meta-
analysis concluded that NSAIDs and H pylori infection were independent but additive 
risk factors for development of peptic ulcer, when taken long term, and separately in 
the ulcer complication of bleeding (116).  
Role of bile in NSAID-induced enteropathy 
Bile contributes to intestinal and gastric damage caused by NSAIDs (23, 117), but 
the biochemical mechanisms have not been established. The severity of NSAID-
enteropathy correlates to the amount of the drug excreted in bile and with the extent 
of enterohepatic circulation (117, 118). Bile duct ligation almost completely abolishes 
the small intestinal macroscopic damage following NSAIDs (119, 120).  
Bile and the NSAIDs excreted in bile play have complex roles in the patho-
genesis of NSAID-induced small intestinal damage. Conventional NSAIDs cause 
small intestinal lesions in rats regardless of whether they are given orally or paren-
terally, but drugs such as aspirin and 6-MNA (the active component of the non-acidic 
pro-NSAID nabumetone), which are not excreted in bile, do not, when given paren-
terally (121). This indicates that the combination of NSAIDs and bile are more toxic 
than either alone. When certain bile acids (taurocholic acid, taurodeoxycholic acid 
and glycocholic acid) were co-administered with indomethacin, the incidence and 
severity of gastric and small bowel damage was significantly increased in rats (122, 
123).  
Bile collected from rats given indomethacin that was then infused into small 
intestinal loops of untreated rats (124) reduced the hydrophobicity of the mucosa and 
caused ileal bleeding. These effects were abolished when phosphatidylicholine was 
added to the bile (from the indomethacin treated rats) prior to instillation into the 
small bowel. Furthermore certain bile acids caused identical damage and this was 
again reversed by addition of equimolar phosphatidylcholine. It was suggested that 
NSAIDs that enter the bile might damage the mucosa, not by a direct action, but by 
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competing for the available protective phosphatidylicholine molecules. Increased 
amounts of unbound bile acids could therefore increase the indomethacin-induced 
(macroscopic) damage. Dial et al similarly showed that bile was cytotoxic following 
indomethacin administration but this effect was reversed when phosphatidylcholine 
was added to the bile-indomethacin mixture (125) again emphasising the NSAID-
phospholipid interaction. Furthermore, although primary and secondary bile acids 
have differential potential to cause damage to intestinal epithelial cßells, they also 
act as effector molecules that activate nuclear and G-protein-coupled receptors; col-
lectively known as bile acid-activated receptors, these help maintain intestinal integri-
ty (126). 
Bile therefore appears to have an important role in the pathogenesis of small 
bowel damage. It has been shown to maintain and disrupt intestinal integrity. The 
choice of the bile acids used in a study is important because bile acids differ in their 
gastrointestinal tolerability (122, 127). For example, taurochendeoxycholic acid in-
creases intestinal inflammation caused by indomethacin, whereas ursodeoxycholic 
acid reduces the damage (128, 129) and chenodeoxycholic acid may be neutral 
(130) 
The effects of diclofenac on bile excretion have been investigated in consid-
erable detail. Diclofenac is metabolized by the liver and the major biliary metabolite, 
diclofenac acyl glucuronide, is excreted by a specific hepatocanalicular conjugate 
export pump. Rats deficient in this transporter have normal bile composition and 
flow, but do not excrete diclofenac or its conjugate into bile (131). These rats had 
significantly less small bowel damage when given diclofenac orally or parenterally. 
Furthermore, bile containing diclofenac glucuronide increased small bowel damage 
in normal rats, and transferase-deficient rats over and above diclofenac and bile 
mixed together. Moreover, increasing the activity of glucuronosyltranferase, which 
increases glucuronidaton of diclofenac, increased small bowel damage. This indi-
cates that biotransformation of diclofenac (acyl glucuronide or its oxidative metabo-
lites) accounts for a significant part of its small bowel toxicity. Of note is the fact that 
most carboxylic acid-NSAIDs are metabolised to acyl-glucoronides in a similar fash-
ion. Although these conjugates are reactive in their own right, they are also deconju-
gated by bacterial beta-glucuronidase yielding aglycone, which is believed to be 
even more toxic (132). In an attempt to assess the importance of bacterial beta-
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glucoronidase (133), researchers gave mice diclofenac (intraperitoneally), with or 
without pre-administration of a specific inhibitor of bacterial beta-glucoronidase. The 
inhibitor reduced the number of small bowel erosions and ulcers significantly. Similar 
results were obtained when indomethacin and ketoprofen were used (134).  
The interaction between biliary excretion of NSAIDs and intestinal bacterial 
deconjugation (which may be enhanced by concomitant treatment with proton pump 
inhibitors (135)) possibly provides an explanation for the mid and distal small bowel 
location of NSAID-enteropathy. However, it is important to remember that there are 
significant differences between species in the extent of enteric hepatic circulation of 
carboxylic NSAIDs (relatively low in humans) (136), although all seem to be associ-
ated with NSAID-enteropathy to a similar extent in humans (137). In particular there 
is very little, if any, biliary excretion of ibuprofen or its metabolites in humans (138), 
but this NSAID is still associated with enteropathy.  
The practical implications from the experiments in animals (119, 120, 139) are 
that co-administration of a bile-binding resin, such as cholestyramine, with NSAIDs 
might reduce or prevent some of the small bowel damage. Co-administration of a 
specific inhibitor of bacterial beta-glucoronidase with NSAIDs might also prevent 
damage, but this has not yet been tested in clinical trials.  
Role of bacteria in NSAID-induced enteropathy 
It is difficult to dissociate the effect of intestinal bacteria on the metabolism of NSAID-
conjugates and formation of secondary bile acids to their more direct role to cause or 
increase inflammation in NSAID-enteropathy. Nevertheless, germ-free rats and rats 
given antimicrobial agents do not develop small bowel ulcers when they are given 
indomethacin (140). Indomethacin-induced enteropathy in mice is associated with 
numerous alterations in the number and type of bacteria (135, 140, 141) The precise 
and specific bacterial alterations (true increases, relative shifts, etc.) and effects are 
well documented, but probably not relevant to humans, because their microbiomes 
differ substantially. 
The mechanisms of interactions between the effects of NSAIDs on the micro-
biome and human cells could be mediated by lipopolysaccharide, a bacterial protein 
that binds to and activates toll-like receptor 4 (TLR4). TLR4 signalling activates nu-
clear factor-κB, resulting in neutrophil recruitment (142, 143). Neutrophils are im-
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portant effector cells in the macroscopic damage due to NSAIDs, demonstrated by 
the findings that neutropenic mice do not develop macroscopic lesions in response 
to NSAIDs (144). These findings might offer therapeutic possibilities, such as inhibit-
ing TLR4 or interfering with neutrophil functions.  
The effects of intestinal bacteria on induction of enteropathy by NSAIDs has 
been studied in humans. A capsule enteroscopy study in volunteers showed that co-
administration of the poorly absorbed anti-microbial rifaximin with NSAIDs prevented 
development of erosions and ulcers (145). Patients with established NSAID enterop-
athy, metronidazole reduced inflammation and bleeding but did not affect intestinal 
permeability (146).  
An alternative approach is to reduce or prevent NSAID-induced small bowel 
damage with probiotics, although results from studies of probiotics have been incon-
sistent. In a clinical trial, the probiotic VSL-3 prevented the small bowel damage due 
to indomethacin (50 mg/day), assessed by fecal levels of calprotectin (147). In pa-
tients taking aspirin and a proton pump inhibitor who had iron-deficiency anaemia, 
the probiotic Lactobacillus casei significantly reduced mucosal damage, based on 
capsule endoscopy analysis, compared with controls (148). However, many addi-
tional studies must be performed before specific probiotics can be recommended for 
prevention or treatment of NSAID-enteropathy in humans.  
Future Directions 
Prevention and treatment of the adverse events of NSAIDs on the gastrointestinal 
tract requires knowledge of mechanisms of pathogenesis of the lesions. The com-
plexities of the pathways to this damage have been evident for a long time, but have 
not received much attention, presumably because the effects of inhibiting COX en-
zymes offer simple and logical explanation for the damage. This hypothesis led to 
development of the COX2-selective agents with increased gastrointestinal safety. 
However, studies of knockout mice (especially COX1- and COX2-knockout mice) 
and development of drugs with highly specific actions increased our understanding 
of the effects of NSAIDs. We now recognize that inhibition of COX1 or COX2 does 
not solely account for the gastrointestinal damage induced by NSAIDs. NSAIDs have 
“topical” effects that damage intestinal cells by disrupting membrane and mucus 
phospholipids and uncoupling of mitochondrial oxidative phosphorylation.  
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NSAIDs increase intestinal permeability in patients (149), leading to low-grade 
intestinal inflammation. Disruption of the intestinal barrier is associated with many 
human small bowel diseases that are distinctively different to the damage seen with 
NSAIDs (43). NSAIDs also have microvascular effects that aggravate inflammation 
and lead to macroscopic damage, such as erosions and ulcers in the stomach and 
the small bowel. It should be noted that these observations relate to the pathogene-
sis of damage, but not necessarily the clinical adverse effects. Clinically serious gas-
tric and small bowel ulcer events of perforation and bleeding involve separate clinical 
and co-morbidity factors (150).  
Our model emphasizes the multi-stage complexities of the pathogenesis and 
the numerous interactive and ongoing synergistic factors that intensify or modulate 
the damage. For example, the increased intestinal permeability that is brought about 
by the “topical” effects of NSAIDs is intensified because of the inflammatory re-
sponse (to luminal aggressors) and the microvascular effects of COX inhibition, etc. 
Conventional NSAIDs cause maximum intestinal damage whereas the various com-
binations of the biochemical actions observed experimentally, such as selective inhi-
bition or absence of COX1 and 2 (without the “topical” effect), “topical” effect com-
bined with COX1 absence or inhibition (without COX2 involvement), “topical” effect 
combined with COX2 absence or inhibition (without COX1 involvement) can increase 
tolerability, but do not fully prevent intestinal damage.  
In patients, strategies to alter or minimize a single biochemical effect of 
NSAIDs, such by co-administration of a phospholipid, esterification of NSAIDs (with 
or without the addition of nitric oxide or hydrogen sulfite moieties), or use of selective 
COX2 inhibitors (which spare COX1 and reduces the “topical” effect) does not re-
move their toxicity. Altering the physical and chemical properties of NSAIDs to alter 
their efficacy or tolerability is impractical, because the same physicochemical proper-
ties of NSAIDs mediate their “topical” effects and effects on COX enzymes. Strate-
gies to interfere with their non-biochemical actions, such as the luminal aggressors, 
could be a more realistic approach for reducing NSAID-induced small bowel damage 
in patients. By analogy inhibition of gastric acid secretion prevents and heals NSAID-
associated ulcers.  
The current model is largely based on findings from rodents, which have 
many differences from humans in physiology, biochemistry, immunology etc., and 
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not least the gastrointestinal tract microbiome. Furthermore, in these studies, 
NSAIDs were administered to the animals at doses that are an order of magnitude 
higher than doses taken by patients, and the compounds used to solubilize NSAIDs 
given to animals are toxic. Extrapolation of data from animal studies to humans 
therefore requires great care. However, some aspects of the damage show remark-
able similarities, such as the increase in intestinal permeability seen with NSAIDs, 
the localization of NSAID enteropathy to the mid to distal small bowel, similar re-
sponses to some therapeutic interventions, etc. Animal experiments are a conven-
ient way to explore pathogenic processes, but findings must be confirmed in human 
studies.  
Many view the clinical importance of NSAID-induced gastropathy to the exclu-
sion of NSAID-induced enteropathy and, moreover, there have been very few at-
tempts to minimize the incidence or clinical impact of NSAID-induced enteropathy. 
This may be because of selective funding for research into the treatment of NSAID-
induced gastropathy, but also because NSAID enteropathy has been perceived as 
being asymptomatic and benign. However, most patients with NSAID-induced enter-
opathy bleed from the small bowel (146, 151), which frequently leads to an iron defi-
ciency anemia (152), occasional hypoalbuminemia, diaphragm disease (6), and even 
death from intestinal perforation with peritonitis (153). Increasing understanding of 
the mechanisms of NSAID-induced damage to the small bowel, should stimulate fur-
ther research and reduce these clinical effects.  
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Table 1. Relationship Between pKa and Uncoupling of Mitochondrial Oxi-
dative Phosphorylation 
Drug pKa Percentage max-
imum uncoupling 
Mean±SEM con-
centration re-
quired for maxi-
mum uncoupling 
(microM/mg pro-
tein) 
Nitrosalicylic acid 
Salicylic acid 
Acetylsalicylic acid 
Diclofenac 
Naproxen 
Flurbiprofen 
Indomethacin 
6-MNA 
Ibuprofen 
Ketoprofen 
2.3 
2.94 
3.5 
4.0 
4.15 
4.22 
4.5 
5.0 
5.2 
5.94 
205 
200 
200 
200 
210 
265 
230 
180 
250 
220 
2.70 ± 1.21 
2.10 ± 1.23 
1.6 ± 1.19 
0.43 ±0.22 
0.61 ± 0.16 
0.51 ± 0.19 
0.15 ± 0.12 
0.46 ± 0.27 
0.28 ± 0.18 
0.38 ± 0.12 
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Piroxicam 
Azapropazone 
6.3 
6.3 
215 
210 
0.20 ± 0.11 
0.02 ± 0.02 
Notes: Data derived from in vitro experiments with conventional NSAIDs. 
The maximum degree of respiration stimulation was similar among the NSAIDs 
tested, but the concentration needed for maximum stimulation differed. The 
more acidic the NSAID the higher concentration required for maximum uncou-
pling (Spearman’s correlation coefficient [r] = 0.87, P<.001; n = 12). 
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Table 2. Results of Studies of Uncoupling and Other Factors That Contribute to Small Bowel Damage From 
NSAIDs 
Reference Drug Uncoupling Mucosal  
Level of 
PGE2 
Intestinal 
vitro vivo  Permeability Inflammation Ulcers 
(75) Flurbiprofen + +  +  + 
 NO-flurbiprofen 0 +  +  + 
        
(73) DNP + + +10% + + 0 
 R-flurbiprofen + + –12% + + 0 
 R + S flurbiprofen  + + –92% + + + 
 S- flurbiprofen + + –89% + + + 
        
(78) Indomethacin + + a Reduction of 
71%–96% 
+ + + 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
22 
 
 Nimesulide + + b 0–75% 0 0 0 
        
(154) DNP + + +12% + + 0 
 Indomethacin + + –89% + + + 
 Aspirin + 0 –88% 0 0 0 
 Aspirin + DNP + + –81% + + + 
        
(79) Indomethacin + + –90% + +  
 Celecoxib 0 0 0% 0 0 0 
        
(36) COX1-/-   –97% 0 0 0 
 COX1+/+ + SC560   –97% 0 0 0 
 COX2-/- (50%) 
(50%) 
  96% 
94% 
0 
+ 
0 
+ 
0 
+ 
DNP, dintirophenol; SC560, selective non-acidic inhibitor of COX1; Cox1+/+, full-length Cox1 gene in mice; Cox1–/–, 
homozygous disruption of Cox1 gene in mice; Cox2–/–, homozygous disruption of Cox2 gene in mice. Approximately 
15% of Cox2–/– mice die from small bowel perforation; 50% of mice had normal intestinal permeability and no intestinal 
inflammation and 50% had small bowel ulcers. 
Uncoupling: 0, no uncoupling; +a, 60%–70% of the mitochondria have uncoupling determined by electron microscopy;  
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+b, 10%–30% of the mitochondria have uncoupling determined by electron microscopy 
Mucosal levels PGE2: percentages indicate increase (+) or decrease (–) from control level 
Permeability (measured by 51CrEDTA) and inflammation (fecal level of calprotectin): 0, unchanged; +, increased 
Number of small bowel ulcers: 0, none; +, present 
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FIGURE LEGENDS 
 
Figure 1. Mechanisms of Gastrointestinal Damage by NSAIDs 
In our model, the interaction between NSAIDs and phospholipids and uncoupling of oxidative phosphorylation damage 
intestinal cells and increase gastrointestinal permeability. Inhibition of COX reduces microvascular blood flow, and lu-
minal aggressive factors modify and amplify this reaction, leading to inflammation, erosions, and ulcers. Principal luminal 
aggressors are acid and pepsin in the stomach and acid, bile, and bacteria in the small bowel.  
 
Figure 2. Structures of Conventional NSAIDs and Derivatives 
Conventional NSAIDs are usually lipid-soluble molecules (often benzene derivatives) with an acidic carboxylic group. The 
analgesic paracetamol has no anti-inflammatory activity and does not cause gastrointestinal damage because it lacks the 
acidic moiety. Derivatives of flurbiprofen, such as nitric oxide flurbiprofen and flurbiprofen dimer (thought to cause less 
intestinal damage than flurbiprofen) are non-acidic because of the esterification of the carboxylic moiety. 
Nabumetone, a pro-NSAID that causes minimal gastrointestinal damage, becomes anti-inflammatory only after conver-
sion in the liver into the active component MNA, which is acidic. 
 
Figure 3. Mechanism of Uncoupling Actions of NSAIDs 
High-energy intermediates feed into the respiratory chain; as energy is released, it is used to pump out hydrogen ions 
into the inter-mitochondrial membrane space. Normally these hydrogen ions re-enter via a channel (ionopore) that is as-
sociated with ATP synthase and this promotes production of ATP. NSAIDs, however, partition into the inner mitochondri-
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al membrane and create similar ionopores that allow hydrogen ions to enter the inner mitochondrial matrix, thereby by-
passing the ATP synthase. The uncoupling (that is, uncoupling the hydrogen gradient from the ATPase activities) by 
NSAIDs leads to cell dysfunction from decreased levels of ATP, calcium release into the cytosol, etc. 
 
Figure 4. Ion Trapping Hypothesis for NSAIDs  
The intracellular concentration of an NSAID in the stomach depends on the interaction between the pKa of the NSAID 
and luminal pH as well as the rate of exit from the cell, which also depends on the pKa of the drug. Furthermore, lipid sol-
ubility, size, and metabolism of the NSAIDs and protein binding have roles in absorption-trapping. The more acidic the 
NSAID, the more it depends on a low gastric pH (an uncharged NSAID partitions through the surface cell membrane 
more effectively that a charged one) for entry into the epithelial cells; once inside, it is again charged (cytosol has a pH of 
7.4) and it accumulates to reach a greater concentration than NSAIDs with pKas that are closer to neutral. Uncoupling 
potency appears to be directly proportional to the pKa of the NSAID. For example, after an oral dose of aspirin (pKa of 
3.5) the drug does not enter the gastric mucosal cells when the gastric lumen is neutral (pH 7.0) because it is fully ion-
ised. However, at a gastric pH of 2, for example, it is uncharged and easily partitions into the cells. Inside the cell, it is ful-
ly ionized because of the intercellular pH (7.4). It can therefore not pass into the circulation, and intracellular concentra-
tions increase to the micromolar range required for uncoupling. A less-acidic NSAID with a pKa of 6.4 is less dependant 
on the luminal pKa for its entry into the gastric cells. However, because it is only partially ionized at the intracellular pH of 
7.4, it is absorbed into the circulation and the intracellular concentrations may only be modestly high in comparison with 
aspirin. Neutralizing the gastric pH with drugs like proton pump inhibitors prevents short-term gastric damage of acidic 
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NSAIDs more effectively than with less acidic NSAIDs. Because of the enormous surface area of the small intestine, the 
charge of the NSAID has only a minor role in its absorption, but ion trapping is still evident.  
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